Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan

Neurology

Volumn 89, Issue 19, 2017, Pages 1995-2001

  Houzen, Hideki ^a   Kondo, Kimito ^b   Niino, Masaaki ^c   Horiuchi, Kazuhiro ^a   Takahashi, Toshiyuki ^d,e   Nakashima, Ichiro ^d,f   Tanaka, Keiko ^g  

^a Obihiro Kosei General Hospital   (Japan)

^b Hokuto Hospital   (Japan)

^c HOKKAIDO MEDICAL CENTER   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

^e Yonezawa National Hospital   (Japan)

^f TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^g NIIGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; STEROID; TACROLIMUS; AQUAPORIN 4; AUTOANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CAUCASIAN; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE DURATION; DRUG MEGADOSE; ETHNIC DIFFERENCE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; INCIDENCE; JAPAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELITIS; MYELOOPTIC NEUROPATHY; ONSET AGE; OPTIC NEURITIS; PLASMA EXCHANGE; PREVALENCE; PRIORITY JOURNAL; SERODIAGNOSIS; BLOOD; DISABILITY; ETHNIC GROUP; HEALTH SURVEY; IMMUNOLOGY; NEUROMYELITIS OPTICA;

ADULT; AGE OF ONSET; AGED; AQUAPORIN 4; AUTOANTIBODIES; DISABILITY EVALUATION; ETHNIC GROUPS; FEMALE; HEALTH SURVEYS; HUMANS; JAPAN; MALE; MIDDLE AGED; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS OPTICA; PREVALENCE;

EID: 85033552362     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000004611     Document Type: Article

References (21)

1. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
2. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
3. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6: 805-815.
4. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-189.
5. Wingerchuk DM, Weinshenker WB. Neuromyelitis optica spectrum disorder diagnostic criteria: sensitivity and specificity are both important. Mult Scler 2017;23:182-184.
6. Hamid SH, Elsone LI, Mutch K, et al. The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates. Mult Scler 2017;23:228-233.
7. Houzen H, Niino M, Kikuchi S, et al. The prevalence and clinical characteristics of MS in northern Japan. J Neurol Sci 2003;211:49-53.
8. Houzen H, Niino M, Hata D, et al. Increasing prevalence and incidence of multiple sclerosis in northern Japan. Mult Scler 2008;14:887-892.
9. Houzen H, Niino M, Hirotani M, et al. Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan. J Neurol Sci 2012;323:117-122.
10. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014;82:474-481.
11. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120: 2059-2069.
12. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114.
13. Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler J 2015;21:845-853.
14. Asgari N, Lillevang ST, Skejoe HPB, et al. A populationbased study of neuromyelitis optica in Caucasians. Neurology 2011;76:1589-1595.
15. Cossburn M, Tackley G, Baker K, et al. The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol 2012;19:655-659.
16. Jacob A, Panicker J, Lythgoe D, et al. The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol 2013;260:2134-2137.
17. Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 2016;79:775-783.
18. Pandit L, Kundapur R. Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India. Mult Scler 2014;20:1651-1653.
19. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012;135:1834-1849.
20. Abboud H, Petrak A, Mealy M, et al. Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler 2016;22:185-192.
21. Kleiter I, Gold R. Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics 2016;13:70-83.